China’s biotech firms move up value chain as drug deals evolve beyond licensing
Many Chinese biotech companies initially relied on out-licensing to fund their pipelines, a model in which a developer sells the rights to an early-stage drug candidate to another company, which then undertakes global development and commercialisation. However, as their resources and ambitions expanded, companies had increasingly moved towards co-development arrangements and broader platform partnerships. Source: …
Continue reading “China’s biotech firms move up value chain as drug deals evolve beyond licensing”